Angelman syndrome: first patient to receive potential therapy in Oxford
3 December 2021
Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.
Department of Paediatrics unveils new logo
30 November 2021
The Department of Paediatrics at the University of Oxford - a world leader in child health research, has launched a new brand identity.
New model for infant leukaemia announced
25 November 2021
The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.
Why it's so hard to treat pain in infants
12 November 2021
Children's Health Neuroimaging
For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.
Oxford to work with Brazil to establish clinical research hub
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
New atlas revealed of bone marrow haematopoiesis during development
5 October 2021
Children's Health Haematology Immunology
A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.
Changes in blood cell production over the human lifetime may hold clues to patterns of disease
16 September 2021
A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.
Promising discovery for treatment of neuromuscular diseases
23 August 2021
Neuromuscular Diseases Publication Research
Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.
Vaccine for TB receives a $1.5 million funding boost
20 August 2021
The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.
University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships
9 August 2021
Awards & Appointments Research
Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.
Oxford vaccine reaches one billion doses released
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
Phase I trial begins of new vaccine against the Plague
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
Oxford Vaccine Group among winners at NHS Parliamentary awards
9 July 2021
Awards & Appointments COVID-19 Vaccinology
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
New book highlights life-saving role vaccines play in prevention of killer diseases
8 July 2021
Public Engagement Publication Vaccinology
'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
COVID-19 Clinical Trials Vaccinology
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
COVID-19 Clinical Trials Vaccinology
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
First trial participants vaccinated with Oxford COVID-19 variant vaccine
28 June 2021
COVID-19 Clinical Trials Vaccinology
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19
28 June 2021
Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study
21 June 2021
COVID-19 Publication Vaccinology
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
Peadiatrics professor recognised in Queen’s Birthday Honours
11 June 2021
Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.